PTAB Allows Amicus Brief in Allergan IPRs

PTAB Allows Amicus Brief in Allergan IPRs

By Margaux A. Savee

In an interesting turn of events, the Board is now permitting amicus briefs in the hotly disputed case between Allergan, Inc. and generic drug makers relating to patents for Allergan’s dry eye drug, Restasis. This appears to be the first time that the Board has allowed amicus briefs in a post-grant challenge.

Read More

A Brief Overview of Pharmaceutical IPRs and Statistical Outcome

A Brief Overview of Pharmaceutical IPRs and Statistical Outcome

By: Jeffrey Kuo and Afia Naaz
Edited by: Margaux Savee

Patent invalidation is a high stakes game for the pharmaceutical industry. Patented drug sales account for about 70% ($244 billion) of pharmaceutical sales in the US, and invalidation of patents at the Patent Trial and Appeal Board (“PTAB”) has an impact on pharmaceutical share prices.

Read on for more information including:

  • Comparing IPR with District Court Litigation of Pharmaceutical Patents
  • Statistical Outcomes of Pharmaceutical IPRs
Read More